Table 2.
Metabolites significantly increased in women relative to men over time.
| Metabolite | P-value | Bonferroni corrected P-value | − log10p | β coefficient | Super pathway | Sub pathway |
|---|---|---|---|---|---|---|
| 1-linoleoyl-GPE (18:2) | 3.71 E−15 | 2.14 E−12 | 14.43 | 0.21 | Lipid | Lysophospholipid |
| 1-palmitoyl-GPA (16:0) | 1.77 E−11 | 1.02 E−08 | 10.75 | 0.20 | Lipid | Lysophospholipid |
| 1-linoleoyl-GPA (18:2) | 5.69 E−10 | 3.29 E−07 | 9.24 | 0.20 | Lipid | Lysophospholipid |
| 1-linolenoyl-GPC (18:3) | 1.57 E−11 | 9.08 E−09 | 10.80 | 0.20 | Lipid | Lysophospholipid |
| 1-stearoyl-GPE (18:0) | 6.74 E−16 | 3.90 E−13 | 15.17 | 0.19 | Lipid | Lysophospholipid |
| 1-palmitoleoyl-GPC (16:1) | 5.95 E−11 | 3.44 E−08 | 10.23 | 0.17 | Lipid | Lysophospholipid |
| 1-arachidonoyl-GPE (20:4n6) | 2.74 E−10 | 1.58 E−07 | 9.56 | 0.16 | Lipid | Lysophospholipid |
| 2-stearoyl-GPE (18:0) | 2.13 E−09 | 1.23 E−06 | 8.67 | 0.16 | Lipid | Lysophospholipid |
| 1-oleoyl-GPE (18:1) | 5.81 E−10 | 3.36 E−07 | 9.24 | 0.16 | Lipid | Lysophospholipid |
| 2-palmitoyl-GPC (16:0) | 7.59 E−09 | 4.39 E−06 | 8.12 | 0.15 | Lipid | Lysophospholipid |
| 1-lignoceroyl-GPC (24:0) | 3.89 E−06 | 2.25 E−03 | 5.41 | 0.15 | Lipid | Lysophospholipid |
| 1-linoleoyl-GPI (18:2) | 9.30 E−08 | 5.37 E−05 | 7.03 | 0.14 | Lipid | Lysophospholipid |
| 1-arachidonoyl-GPC (20:4) | 8.26 E−07 | 4.78 E−04 | 6.08 | 0.13 | Lipid | Lysophospholipid |
| Sphingomyelin (d18:2/14:0, d18:1/14:1) | 6.93 E-29 | 4.01 E−26 | 28.16 | 0.28 | Lipid | Sphingomyelin |
| Sphingomyelin (d17:2/16:0, d18:2/15:0) | 1.33 E−21 | 7.70 E−19 | 20.88 | 0.26 | Lipid | Sphingomyelin |
| Sphingomyelin (d17:1/14:0, d16:1/15:0) | 1.92 E−18 | 1.11 E−15 | 17.72 | 0.24 | Lipid | Sphingomyelin |
| Sphingomyelin (d18:2/21:0, d16:2/23:0) | 4.11 E−13 | 2.38 E−10 | 12.39 | 0.18 | Lipid | Sphingomyelin |
| Sphingomyelin (d18:1/21:0, d17:1/22:0, d16:1/23:0) | 3.76 E−10 | 2.17 E−07 | 9.43 | 0.17 | Lipid | Sphingomyelin |
| Sphingomyelin (d18:1/19:0, d19:1/18:0) | 1.28 E−09 | 7.38 E−07 | 8.89 | 0.15 | Lipid | Sphingomyelin |
| Sphingomyelin (d18:2/23:0, d18:1/23:1, d17:1/24:1) | 2.74 E−09 | 1.58 E−06 | 8.56 | 0.15 | Lipid | Sphingomyelin |
| Tricosanoyl sphingomyelin (d18:1/23:0) | 5.28 E−08 | 3.05 E−05 | 7.28 | 0.13 | Lipid | Sphingomyelin |
| Sphingomyelin (d18:1/25:0, d19:0/24:1, d20:1/23:0, d19:1/24:0) | 4.60 E−05 | 2.66 E−02 | 4.34 | 0.11 | Lipid | Sphingomyelin |
Significant results presented following mixed-effects modeling of each of the 578 individual metabolites measured at day 0, 3 and 7. All estimates adjusted for age, SAPS II, admission diagnosis, 25(OH)D at day 0, absolute change in 25(OH)D level at day 3 and plasma day (as the random-intercept). A multiple test-corrected threshold of P-value < 8.65 × 10–5 was used to identify all significant associations. GPC is glycerophosphorylcholine; GPE is glycerophosphoethanolamine; GPI is glycosylphosphatidylinositol. Positive β coefficient values indicate higher abundance in females relative to males.